Celldex stock rating reiterated at Buy by Canaccord ahead of data release

Canaccord Genuity is reiterating its Buy rating on Celldex Therapeutics (CLDX) with a $64 price target ahead of the presentation of 76-week Phase II data for barzolvolimab in chronic spontaneous urticaria (CSU) at the EAACI Congress 2025; this data will include analysis of angioedema improvements. While Celldex's Q1 EPS of ($0.81) missed estimates, the company maintains a strong cash position of $673.3 million, expected to fund operations through 2027, and is actively developing barzolvolimab in Phase 3 trials, with several analysts maintaining positive ratings despite some price target adjustments.

Analysis

Celldex Therapeutics is approaching a significant clinical catalyst with the scheduled presentation of 76-week Phase II data for its lead candidate, barzolvolimab, in chronic spontaneous urticaria (CSU) at the EAACI Congress 2025, an event designated as a Late Breaking oral presentation. The company will also present additional 52-week analysis highlighting improvements in angioedema. Canaccord Genuity has reiterated its Buy rating and a $64.00 price target on CLDX, substantially above the current $20.42, anticipating that positive data could present a buying opportunity. While Celldex reported a Q1 earnings per share of ($0.81), missing analyst expectations of ($0.73)-($0.74), its financial position remains robust with $673.3 million in cash reserves, projected to fund operations through 2027. This financial runway supports ongoing Phase 3 studies for barzolvolimab in CSU and other indications. Analyst sentiment is broadly constructive, with H.C. Wainwright maintaining a Buy despite adjusting its target to $50 from $80, Cantor Fitzgerald upholding an Overweight rating with a $67 target, and Morgan Stanley initiating with an Overweight rating and a $46 target, reflecting confidence in barzolvolimab's potential. The appointment of Denice M. Torres to the Board of Directors also adds experienced oversight, positioning Celldex for a dynamic period as it advances its clinical programs.

Key Decisions for Investors

• Investors should closely monitor the upcoming 76-week Phase II barzolvolimab data presentation and the subsequent company conference call, as these are pivotal near-term catalysts for Celldex Therapeutics.
• The significant analyst-projected upside, exemplified by Canaccord Genuity's $64 target, and the company's robust cash reserves extending through 2027, suggest potential for appreciation if clinical results are favorable, despite a recent Q1 EPS miss.
• Investors should carefully weigh the high-reward potential highlighted by bullish analyst ratings against the inherent development risks common in the biopharmaceutical sector, as reflected in the wide $31 to $90 analyst price target range.